Clinical Trials Browser

Phase 2/3 × Neoadjuvant Therapy × 1 year × Clear all

NCT04669496 2025-09-04

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Phase 2/3 Active not recruiting

Gastrointestinal

Cholangiocarcinoma

NCT07134218 2025-08-21

Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer

Phase 2/3 Not yet recruiting

Gastrointestinal

Rectal Neoplasms